Indeed, GLP-1 agonists displayed an unexpected effectiveness in treating morbid obesity and its comorbidities [36], and seminal data showed a reduction in OSA symptoms burden and disease severity (expressed as AHI value) associated with GLP-1 receptor agonists [37,38,39]. Here, GCG is linked to obstructive sleep apnea syndrome.